Author

Elie A. Traer

Oregon Health & Science UniversityORCID 0000-0001-8844-2345Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioinformatics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Assay:scATAC-seq· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Catherine Choy SmithiD· 2 shared Sunil Kumar JoshiiD· 2 shared Adam B. OlsheniD· 1 shared Aditi ChatterjeeiD· 1 shared Alexander E. PerliD· 1 shared Alisa DamnernsawadiD· 1 shared Andrew Koh· 1 shared Anupriya AgarwaliD· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Catherine Choy SmithORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedJun 2, 2026

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors

Aditi Chatterjee, Moaath K. Mustafa Ali, Christopher M. Bailey…·Maria R. Baer

This study shows that S1P receptor modulators resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors by inhibiting downstream signaling pathways.

2 citationstop 4%

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 2, 2025

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance

Vanessa Elaine Kennedy, Cheryl A.C. Peretz, Anushka Walia…·Catherine Choy Smith

4 citations

humanscRNA-seq

𝕏 PostBluesky

BioinformaticsbioRxivPreprintJun 4, 2021

Utilizing proteomics and phosphoproteomics to predict ex vivo drug sensitivity across genetically diverse AML patients

Sara J.C. Gosline, Cristina E. Tognon, Michael D. Nestor…·Karin Rodland

The paper predicts ex vivo drug sensitivity in AML patients using proteomic and phosphoproteomic signatures, showing better accuracy than mutation or mRNA-based signatures.

DOI 10.1101/2021.06.04.447154

humanproteomics

𝕏 PostBluesky